Efficacy, Safety, and Tolerability Study of Oral Full-Spectrum MicrobiotaTM (CP101) in Subjects With Autism Spectrum Disorder and Associated GI Symptoms (SPROUT)
Study Details
Study Description
Brief Summary
Adolescent autism spectrum disorder subjects with associated GI symptoms will be randomized to receive oral dosing of CP101 capsules in Treatment Group I or matching placebo capsules in Treatment Group II. The purpose of this study is to demonstrate the safety and effectiveness of CP101 in subjects with ASD and associated GI symptoms.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Phase 2 |
Detailed Description
This is a Randomized Double-Blind Placebo Controlled Study of CP101 (Full-Spectrum Microbiota®) in Children with Autism Spectrum Disorder and Associated Gastrointestinal Symptoms
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: CP101 CP101 (Full Spectrum Microbiota) Capsule |
Drug: CP101
Orally administered donor derived full spectrum microbiota
Other Names:
|
| Placebo Comparator: Placebo Placebo for CP101 |
Drug: Placebo
Placebo for CP101
|
Outcome Measures
Primary Outcome Measures
- Childhoood Autism Rating Scales-2 (CARS-2) [24 weeks]
Two 15-item rating scales completed by the clinician (each designed for a different population); and an unscored Parent/Caregiver Questionnaire
Secondary Outcome Measures
- Aberrant Behavior Checklist-2 (ABC-2) [55 weeks]
Scoring scale range from 1-3 for a 58 question, 5 behavior category assessments. All categories summed for individual total scores (7-48). Individual total scores determine severity (the higher, the more severe).
- Social Responsiveness Scale-2 (SRS-2) [55 weeks]
Total Score; Scores for 5 Treatment Subscales; Scores for 2 DSM-5 Compatible Subscales
- Parent Global Impressions-III (PGI-III) [55 weeks]
19 question assessment evaluating parent observations from "much worse" to "much better".
- Gastrointestinal Symptom Rating Scale (GSRS) [55 weeks]
Contains 15 items, uses a seven-graded Likert scale, where 1 represents the most positive option and 7 the most negative one.
- Gastrointestinal Stool & Symptom Questionnaire for Autism (GSSQA) [55 weeks]
17 item assessment evaluating GI symptoms on a scale from "Not at all" to "Almost always".
- Reynolds Intellectual Assessment Scales-2-Nonverbal (RIAS-2-NV) [55 weeks]
IQ test with 8 sub-categories. Scores from each category summed, then indexed
- Autism Diagnostic Interview-Revised (ADI-R) [55 weeks]
The ADI-R provides a diagnostic algorithm for autism as described in both the ICD-10 and DSM-IV. The instrument focuses on behavior in three main areas: qualities of reciprocal social interaction; communication and language; and restricted and repetitive, stereotyped interests and behaviors.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Male or Female ages 5 to 17
-
Diagnosis of ASD by health care provider
-
CARS-2 score ≥35 by the study evaluator
-
1 year history of chronic abnormal bowel function with/without GI symptoms
-
GSRS/Constipation sub-score ≥3.0, or/and GSRS/diarrhea sub-score ≥3.0, during Screening
Exclusion Criteria:
-
Inability to ingest intact capsules.
-
Change or anticipated change of prescription medications and/or nutrition supplement and/or therapy to treat ASD symptoms
-
Prior history, evidence, or diagnosis of inflammatory bowel disease or chronic autoimmune GI disease
-
Below 5th percentile for weight on Centers for Disease Control and Prevention (CDC) growth chart based on age
-
History of fecal microbiota transplantation (FMT) for any condition, regardless of route of administration within 12 months of Screening, or plan to undergo during the study
-
History of epilepsy or any other seizure (except febrile seizure) disorder.
-
Enrollment in any other investigational drug or device study within 8 weeks prior to investigational study medication (CP101/placebo) administration or within 5 half-lives of the last dose of the previous investigational compound, whichever is longer.
-
Major intra-abdominal surgery within the past 60 days prior to Screening (excluding appendectomy or cholecystectomy) and/or planned invasive surgery/hospitalization during the study.
-
Use of systemic antibiotics, systemic antiviral, or systemic antifungal (non-topical) for any condition during 8 weeks prior to Screening, or any anticipated use of above for any condition (e.g., frequent otitis media requiring antibiotics) before EOT (Week 24).
-
Recent change or anticipated change of non-dietary probiotics.
-
Any clinically significant condition that would jeopardize the safety or rights of the subject, or would confound the results of the study, in the opinion of the Principal Investigator.
-
Clinically significant laboratory abnormalities at Screening at the discretion of the Principal Investigator.
-
Pregnant, breast-feeding, or positive pregnancy test at Screening (for females of child-bearing potential) or for sexually active subjects (as determined by the Principal Investigator), who refuses to practice an acceptable form of birth control for the duration of the study.
Contacts and Locations
Locations
No locations specified.Sponsors and Collaborators
- Finch Research and Development LLC.
Investigators
None specified.Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CP101-ASD-203